ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Guardant Health Inc

Guardant Health Inc (GH)

30.21
-1.30
(-4.13%)
Closed June 15 4:00PM
30.0001
-0.2099
(-0.69%)
After Hours: 7:33PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
30.0001
Bid
29.75
Ask
31.00
Volume
1,451,644
29.55 Day's Range 31.44
15.81 52 Week Range 41.06
Market Cap
Previous Close
31.51
Open
31.25
Last Trade
1
@
30.61
Last Trade Time
Financial Volume
$ 43,902,142
VWAP
30.2431
Average Volume (3m)
2,414,816
Shares Outstanding
121,712,724
Dividend Yield
-
PE Ratio
-7.67
Earnings Per Share (EPS)
-3.94
Revenue
563.95M
Net Profit
-479.45M

About Guardant Health Inc

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selectio... Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Show more

Sector
Medical Laboratories
Industry
Medical Laboratories
Headquarters
Dover, Delaware, USA
Founded
1970
Guardant Health Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker GH. The last closing price for Guardant Health was $31.51. Over the last year, Guardant Health shares have traded in a share price range of $ 15.81 to $ 41.06.

Guardant Health currently has 121,712,724 shares outstanding. The market capitalization of Guardant Health is $3.68 billion. Guardant Health has a price to earnings ratio (PE ratio) of -7.67.

Guardant Health (GH) Options Flow Summary

Overall Flow

Bullish

Net Premium

406k

Calls / Puts

100.00%

Buys / Sells

33.33%

OTM / ITM

33.33%

Sweeps Ratio

0.00%

GH Latest News

Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer

Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes Operational improvements streamline workflow and shorten time to results...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.62015.7085976039528.3832.328.0508181641830.55589738CS
43.505113.22928854526.49532.322.4268043127.43446511CS
1212.490171.331239291817.5132.315.81241481622.57080119CS
260.94013.2350309704129.0632.315.81201529222.47310564CS
52-8.2899-21.650300339538.2941.0615.81186665126.58413838CS
156-91.5399-75.3166858647121.54133.8215.81151791443.45241882CS
260-59.9199-66.636899466289.92181.0715.81132132160.92976628CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

GH Discussion

View Posts
Monksdream Monksdream 2 weeks ago
The American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples,[1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013.[2][3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a technique which "involves detecting and monitoring tumor fragments circulating in the patient's bloodstream", as an alternative to traditional tissue biopsies.[4] The duo met at Stanford University in 2002 and worked together at Illumina, until Talasaz left in 2012.[5]
👍️0
SubPenny0001 SubPenny0001 3 weeks ago
I would add GH with EXAS both would score on the final outcome. FDA is expected to decide whether to approve Shield later this year.
👍️0
jedijazz jedijazz 4 weeks ago
For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 💯 1
jedijazz jedijazz 4 weeks ago
$GH -Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.
👍️ 1 💪 1
jedijazz jedijazz 4 weeks ago
Guardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New England Journal of Medicine. An FDA Advisory Panel is scheduled to review the PMA application on May 23.

The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting will be available at the DDW website.

For information and updates from the meeting, follow Guardant Health on LinkedIn, X (Twitter) and Facebook. $GH
👍️ 1 💪 1 😍 1
jedijazz jedijazz 4 weeks ago
$GH Guardant Health Inc NASDAQ -Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 16 2024 - 8:05AM


Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.

“One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of Guardant Health. “The data we will share at DDW underscores the important role that our Shield blood test can have in both improving screening rates and in detecting more colorectal cancer at an early stage, when it is most treatable. We look forward to sharing this important data at DDW.”
👍️ 1 💯 1
DewDiligence DewDiligence 1 year ago
GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer:

https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html

https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html

GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample.

EXAS is +24%/AH, adding about $2B(!) to its market cap.

In #msg-168735158 (from May 2022), I said: Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.I stand by that.
👍️0
jerseyboy jerseyboy 3 years ago
I'm still feeling very good about owning this stock. There is no way I'll sell this before the next five years.
👍️0
jerseyboy jerseyboy 3 years ago
I like the nice, gradual, consistent rise in the share price. I think there is no way to lose money here, and I think the gains will be very substantial over the next two to three years.
👍️0
jerseyboy jerseyboy 4 years ago
So am I. This is THE company I have chosen in which to put my investment dollars that I feel is both a high-growth situation and one in which I am certain not to lose money.
👍️0
PR_12 PR_12 4 years ago
2-3 years I'm thinking this is @ 3-5X current share price
👍️0

Your Recent History

Delayed Upgrade Clock